Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213003 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Islet Cells Transplanted Onto the Omentum
A Phase 1 study, sponsored by Rodolfo Alejandro.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02213003: Completed Phase 1 study, sponsored by Rodolfo Alejandro.
NCT02213003 is a Phase 1 study that has completed, run by Rodolfo Alejandro. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02213003, a Phase 1 study, has completed, sponsored by Rodolfo Alejandro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Current islet transplantation into the portal vein of the liver has shown the unique ability of islets to stabilize blood glucose levels and prevent severe hypoglycemia in a selected group of subjects with Type 1 diabetes. The main limitations of islet transplantation are the need for systemic immunosuppression to maintain function and the loss of islet function over time. Additionally, many studies have demonstrated that the current site of transplantation in the liver is not an ideal site due to several factors. These factors include (1) significant liver inflammation following islet infusion; (2) potential for life-threatening procedure-related complications such as bleeding and thrombosis; (3) high levels of immunosuppressive drugs and GI toxins in the liver contributing to islet toxicity; (4) the inability to retrieve islets after infusion; and (5) development of graft dysfunction in a number of recipients of intrahepatic allogeneic and autologous islets. The implantation of islets into the omentum will allow adequate engraftment of islets onto the omentum and will lead to comparable or superior functional and clinical outcomes than in the traditional intrahepatic site.
Primary Outcome
Composite outcome measured by the proportion of subjects with HbA1c level of \</= 6.5 % and free of severe hypoglycemic events after omentum islet transplant
Interventions
- BIOLOGICAL Islet transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-09 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 1 |
What the finished NCT02213003 record still lists
NCT02213003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Islet transplantation is the first listed.
NCT02213003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02213003 about?
NCT02213003 is a clinical study titled "Allogeneic Islet Cells Transplanted Onto the Omentum". Current islet transplantation into the portal vein of the liver has shown the unique ability of islets to stabilize blood glucose levels and prevent severe hypoglycemia in a selected group of subjects with Type 1 diabetes. The main limitations of islet transplantation are the need for systemic immun...
What is the current status of trial NCT02213003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-09. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT02213003?
The interventions under investigation include: Islet transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT02213003?
This trial is sponsored by Rodolfo Alejandro, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02213003's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia